

## Polyvalent Nucleic Acid Nanostructures

Joshua I. Cutler,<sup>†</sup> Ke Zhang,<sup>†</sup> Dan Zheng, Evelyn Auyeung, Andrew E. Prigodich, and Chad A. Mirkin\*


Department of Chemistry and International Institute for Nanotechnology, Northwestern University, 2145 Sheridan Road, Evanston, Illinois 60208-3113, United States

**S** Supporting Information

**ABSTRACT:** Polyvalent oligonucleotide–nanoparticle conjugates possess several unique emergent properties, including enhanced cellular uptake, high antisense bioactivity, and nuclease resistance, which hypothetically originate from the dense packing and orientation of oligonucleotides on the surface of the nanoparticle. In this Communication, we describe a new class of polyvalent nucleic acid nanostructures (PNANs), which are comprised of only cross-linked and oriented nucleic acids. We demonstrate that these particles are capable of effecting high cellular uptake and gene regulation without the need of a cationic polymer co-carrier. The PNANs also exhibit cooperative binding behavior and nuclease resistance properties.

The natural defenses of biological systems for exogenous oligonucleotides, such as synthetic antisense DNA and siRNA, present many challenges for the delivery of nucleic acids in an efficient, non-toxic, and non-immunogenic fashion.<sup>1–3</sup> Indeed, because nucleic acids are negatively charged and prone to enzymatic degradation, researchers have historically relied on transfection agents such as cationic polymers,<sup>4–6</sup> liposomes,<sup>7</sup> and modified viruses<sup>8</sup> to facilitate cellular entry and protect DNA from degradation. However, each of these materials is subject to several drawbacks, which include toxicity at high concentrations, inability to be degraded biologically, and severe immunogenicity.<sup>9</sup> The recently introduced polyvalent nucleic acid–nanoparticle (NP) conjugates (inorganic NPs densely coated with highly oriented oligonucleotides) pose one possible solution for circumventing these problems in the context of both antisense and RNAi pathways.<sup>10–15</sup> Remarkably, these highly negatively charged structures (zeta potential < –30 mV) do not require cationic transfection materials or additional particle surface modifications and naturally enter all cell lines tested to date (over 50, including primary cells). Further work has shown the cellular uptake of these particles to be dependent upon DNA surface density: higher densities lead to higher levels of particle uptake.<sup>16</sup> The high-density polyvalent nucleic acid surface layer is believed to recruit scavenger receptors from the cells that facilitate endocytosis.<sup>16,17</sup> Moreover, the ion cloud associated with the high-density oligonucleotide shell, combined with steric inhibition at the surface of the particles, inhibits enzymatic nucleic acid degradation and activation of the enzymes that trigger the innate immune response of certain cells.<sup>18,19</sup> These surprising observations pose the question, will polyvalent nucleic acids alone (lacking a particle core) readily enter cells without the need for a cationic polymer co-carrier? If so, one could create new

**Scheme 1. Synthesis of the PNAN from Alkyne-Modified 3'-Thiolated DNA**




gene regulation, drug delivery, and imaging systems based solely on high-density polyvalent nucleic acid nanostructures (PNANs) and bypass some of the issues that surround inorganic particle-based systems,<sup>20–22</sup> especially those pertaining to long-term toxicity.<sup>23–25</sup> Herein, we report a strategy for synthesizing monodisperse, spherical high-density polyvalent DNA and DNA–RNA hybrid nanostructures with no inorganic cores. These new nanostructures are composed entirely of oligonucleotides, maintain the unique binding properties of nucleic acid–inorganic NP conjugates (*vide infra*), exhibit the ability to enter cells without co-carriers, and engage the RNAi pathway in human cells.

Recently, we discovered that propargyl-ether-modified polymers could be adsorbed and cross-linked on AuNP surfaces in water.<sup>26</sup> Subsequent oxidative dissolution of the gold core yields hollow nanostructures that closely match the size and shape of the AuNP template. This novel approach takes advantage of the AuNP's ability to act as both a template and a catalyst. To synthesize the PNANs, we prepared a novel class of oligonucleotides with a sequence of thymine (T) bases modified with propargyl ether groups linked through an amidohexylacrylamido linker to the 5 position of the T base, and a subsequent spacer of five unmodified T bases for flexibility and accessibility of the remaining sequence of ~20 base pairs (Scheme 1). The final nucleotides can be composed of either DNA or RNA designed for recognition purposes in the context of antisense or siRNA gene knockdown, respectively. These structures readily adsorb onto the surfaces of citrate-stabilized AuNPs (5, 10, 20, and 30 nm evaluated in this study) and can be loaded to ~90 strands per 10 nm particle (at a density of ~0.28 strands/nm<sup>2</sup>). Cross-linking takes place between the propargyl groups on the surface of the particle and along the modified bases, creating a densely packed, cross-linked shell of DNA. Indeed, the loading is

**Received:** April 12, 2011


**Published:** June 01, 2011



**Figure 1.** (A) Agarose gel electrophoresis (1%) of PNANs synthesized from a range of template sizes (5, 10, 20, 30 nm). (B) Number of DNA strands per AuNP determined using  $^{32}\text{P}$ -radiolabeled DNA for AuNPs of different sizes (5–30 nm). Line shows the relative surface area of respective AuNPs. (C) UV-vis spectra corresponding to the TEM images in (D) during the dissolution process, showing a blue shift of the plasmon resonance from 524 to 518 nm as the AuNP core is oxidatively dissolved. (D) TEM of alkyne–DNA-modified AuNPs (1), PNANs encasing partially dissolved AuNPs (2), and fully formed PNANs negatively stained with uranyl acetate (3).

approximately twice the loading of oligonucleotides with only alkylthiol groups under optimized conditions.<sup>27,28</sup> Upon removal of the AuNP template with 1  $\mu\text{M}$  aqueous KCN, PNANs with the shape of the original AuNP template are formed. The size of the PNANs can also be easily controlled by choosing AuNP templates of appropriate sizes (5–30 nm); larger PNANs made of more DNA strands show lower mobility in agarose gel electrophoresis (Figure 1A,B and Supporting Information, Figure S1).

In contrast with citrate-capped AuNPs, which rapidly aggregate and turn blue due to plasmon resonance red shifting upon the addition of KCN,<sup>29</sup> the gold particles encased in a shell of alkyne-modified DNA do not aggregate during oxidative dissolution but rather slowly lose color with a concomitant blue shift in the plasmon resonance from 524 to 515 nm, suggesting a decrease in size of the particles (original size = 10 nm, Figure 1C).<sup>30</sup> Indeed, transmission electron microscopy (TEM) images of samples of the alkyne–DNA-coated AuNPs during this dissolution process are consistent with the conclusion that the gold core is slowly dissolved and eventually yields hollow structures with a cross-linked shell of DNA (visualized by uranyl acetate staining, Figures 1D and S1). Highly polyvalent DNA nanostructures often exhibit a high degree of cooperative binding with complementary nucleic acids, as evidenced by their association and thermal dissociation behavior.<sup>31</sup> In principle, the PNAN structures should exhibit high cooperativity, as manifested in a sharp melting transition when complexed with particles with complementary sequences. We prepared two sets of PNANs with strands that are complementary to each other and labeled them internally with fluorescein and Cy3, respectively; these two dyes can form a fluorescence resonance energy transfer (FRET) pair when they encounter each other through hybridization of the




**Figure 2.** (A) Schematic of two PNANs designed to exhibit FRET upon hybridization, each having either a FITC or a Cy3 dye incorporated in the alkyne–DNA strand. (B) Photographs of PNANs under UV illumination: (1) FITC-labeled PNANs, (2) Cy3-labeled PNANs, (3) mixture of FITC- and Cy3-labeled PNANs in Nanopure water, (4) solution from 3 at 150 mM NaCl, and (5) solution from 4 after 30 min. (C) FRET signal (solid blue) is observed when the FRET PNAN pair is hybridized at room temperature. Upon melting, the FRET signal (565 nm) disappears and donor fluorescence (520 nm) becomes dominant (solid red). Dashed lines show respective Cy3- or FITC-PNAN fluorescence. (D) Melting analysis of free DNA, DNA–AuNP conjugate, and PNAN, each hybridized to a complementary DNA/particle. PNANs exhibit a sharper melting transition, similar to that of DNA–AuNPs, unlike free DNA duplexes.

particles (Figure 2A). When these particles are combined in Nanopure water, one observes only the green fluorescence of fluorescein under UV illumination. However, when the NaCl concentration is raised to 150 mM, the orange fluorescence from the Cy3 due to FRET is immediately observed, and within minutes macroscopic DNA-interconnected assemblies of PNANs form and begin to precipitate (Figure 2B). The green-to-orange color change is reversible with increasing temperature and is analogous to the red-to-purple plasmonic shift observed for aggregated DNA–AuNPs.<sup>13</sup> These visual observations are further confirmed with fluorescence emission measurements. Pre-hybridized PNANs show a dominant FRET signal at 565 nm with minimal donor fluorescence following excitation at 450 nm (Figure 2C). Upon melting, the FRET signal disappears, and donor fluorescence is observed at 520 nm.

We then analyzed the melting properties of these aggregates by UV-vis spectroscopy, as the position and breadth of the melting transition temperature ( $T_m$ ) of the assembled NPs are important parameters for evaluating the quality of the PNANs. The free strand duplexes of the same sequences exhibit  $T_m \approx 24$  °C and a typical broad full width at half-maximum (fwhm,  $>10$  °C) of the derivative of the melting curve. Remarkably, the aggregates exhibit an increased ( $T_m \approx 42$  °C) and much narrower melting transition (fwhm of the derivative  $\sim 2$  °C), indicative of polyvalent DNA interactions (Figure 2D). The melting behavior is identical to that of the undissolved AuNP system, with a slight decrease in  $T_m$  ( $\sim 3$  °C), which is likely due to the swelling of the particles (with a concomitant decrease in DNA density) as observed by dynamic light scattering (DLS) (Figure S2). These data demonstrate that the recognition of the DNA binding region of the propargyl-ether-modified strand is






**Figure 3.** (A) Schematic of nuclease degradation assay. DNase I is used to degrade FITC-labeled DNA strand hybridized to a Dabcyl-labeled PNAN, wherein FITC fluorescence is quenched. Upon enzyme action, the fluorescence signal increases due to release of FITC-containing fragments, and a degradation rate can be determined. (B) DNA degradation following addition of DNase I to free DNA duplexes, DNA–AuNPs, and PNANs monitored by fluorescence intensity.

unaffected by the cross-linking chemistry occurring near the 3' region of the strand. Another measure of PNAN DNA density is their ability to resist nuclease degradation due to their high local sodium ion concentration and steric inaccessibility of the nucleases to the DNA.<sup>18</sup> We synthesized PNANs that were modified with an internal Dabcyl quencher and hybridized them to complementary fluorescein-labeled reporter strands ( $\sim 10$  per particle). The fluorescence of the reporter strand is quenched when hybridized to the Dabcyl-functionalized PNANs; however, when introduced to an enzyme specific for DNA duplex degradation (DNase I), the fluorophores are released and an increase in fluorescence can be observed (Figure 3A). Upon incubation with DNase I, the duplexes of the PNANs are more slowly degraded (rate  $\sim 4$  times slower) as compared to the free duplexes and nearly identical to PNANs that have not had their Au core dissolved (Figure 3B).

With confirmation that PNANs retain cooperative binding and nuclease resistance properties similar to those of the AuNP system, we evaluated their ability to enter human cells and facilitate gene knockdown via the RNAi pathway. Human squamous carcinoma cells (SCC12) were incubated with PNANs synthesized from 5'-Cy5-labeled DNA for 24 h *in the absence* of any cationic transfection agents. Strikingly, PNANs readily enter these cells despite being composed of only negatively charged oligonucleotides. Entry of PNANs into SCC12 cells was qualitatively analyzed by confocal fluorescence microscopy (Figure 4A); however, fluorescence labeling in this case may suffer from self-quenching due to the closely packed DNA strands that comprise the PNAN, and therefore it is not ideal for quantitative measurements. Radiolabeling provides a quantitative way of measuring cellular uptake and internalization of the PNANs, and to this end, we synthesized PNANs from 5'-<sup>32</sup>P-radiolabeled DNA, as the radioactivity of the free strand could be correlated to both strands per particle and particle concentration. Remarkably, PNANs enter cells in very high numbers ( $5.27 \times 10^6$  particles/cell) after 24 h incubation at 10 nM concentration, and at nearly identical levels to the DNA–AuNP system ( $5.09 \times 10^6$  particles/cell) (Figure 4B). It was previously revealed that DNA–AuNP conjugates recruit extracellular proteins as a first step in their cellular internalization, a phenomenon that results in an increase in the hydrodynamic diameters of the particles upon incubation in cell culture media.<sup>16</sup> We monitored the size of the



**Figure 4.** (A) Confocal micrograph of SCC12 cells incubated with 1 nM Cy5-labeled PNANs for 24 h. Cell nuclei are stained with Hoechst 33342. (B) Cell uptake of DNA–AuNP conjugates and PNANs quantified by using radiolabeled alkyne–DNA and expressed as the number of particles per cell. Both constructs show similar high cell uptake that is dependent on concentration. (C) Cytotoxicity measurement of PNANs and Lipofectamine 2000 as measured by MTT assay. (D) EGFR gene knockdown using DharmaFECT, siRNA–AuNP conjugates, and PNANs, determined by qRT-PCR. Inset shows Western blot of EGFR when PNAN is used compared to non-treated cells. GAPDH is used as an internal reference.

PNANs in media by DLS. Comparing with the DNA–AuNP system, which showed an increase of size from  $29.1 \pm 0.5$  to  $36.7 \pm 2.4$  nm after 30 min incubation with cell growth media containing 10% FBS, the PNANs also showed a size increase from  $40.2 \pm 2.9$  to  $48.3 \pm 7.8$  nm. These data demonstrate that high-density polyvalent DNA by itself can facilitate cellular entry without the need for a cationic co-carrier or physical membrane disruption, such as electroporation or sonication, which usually lead to reduction in cell survival rates.<sup>32,33</sup> Indeed, no cytotoxicity is observed for PNANs, even at high concentrations (Figure 4C). Conversely, Lipofectamine2000 reduces the cell survival rate to 0% when one attempts to transfer 20% of the DNA delivered by PNANs into SCC12 cells.

After establishing that PNANs can enter cells through polyvalent-DNA-mediated uptake, we synthesized siRNA-based PNANs targeting the epidermal growth factor receptor (EGFR) expressed in SCC12 cells. To compare the effectiveness of the siRNA-functionalized PNANs to conventional transfection systems, SCC12 cells were incubated with DharmaFECT-complexed EGFR siRNA, EGFR siRNA–AuNPs, EGFR siRNA-functionalized PNANs, and scrambled siRNA-functionalized PNANs at a final concentration of 5 nM for 72 h. The cells were then harvested and analyzed for their protein content by Western blotting and mRNA levels by quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR). Protein levels of EGFR were significantly reduced by EGFR siRNA–AuNPs and EGFR siRNA PNANs, relative to internal control glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Furthermore, mRNA levels of EGFR were reduced by 81% when AuNP–siRNA conjugates were used, and by 82% when siRNA-based PNANs were used (Figure 4D).

The results reported herein show that it is possible to use nanostructures composed entirely of nucleic acids to effect cellular transfection and gene regulation, provided the nucleic acids are presented in a high density and oriented form. The work

challenges the notion that one must complex nucleic acids with positively charged synthetic polymers, lipids, or metal ions to create effective platforms for transfecting the nucleic acids across cell membranes. Indeed, these PNANs are the first core-free structures with high-density DNA shells that are capable of cellular internalization and gene knockdown. As such, they have the potential to bypass some of the disadvantages of conventional co-carrier routes, including issues pertaining to immunogenicity and nucleic acid lifetime. Previous efforts in developing agents targeted for gene therapy have largely focused on the properties of the transfection co-carrier.<sup>34,35</sup> The results here imply that future studies should look beyond the chemical and biological traits of the co-carrier, to include the morphology, density, and arrangement of the nucleic acid construct itself.

## ■ ASSOCIATED CONTENT

**S Supporting Information.** Experimental procedures, DNA/RNA sequences, and additional characterization data. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## ■ AUTHOR INFORMATION

### Corresponding Author

chadnano@northwestern.edu

### Author Contributions

<sup>†</sup>These authors contributed equally.

## ■ ACKNOWLEDGMENT

C.A.M. acknowledges the NCI-CCNE and NSF for support of this research. E.A. acknowledges the NDSEG for a Graduate Research Fellowship. A.E.P. acknowledges Northwestern University for a Ryan Fellowship. TEM was carried out in the EPIC facility of NUANCE Center at Northwestern University. NUANCE Center is supported by NSF-NSEC, NSF-MRSEC, Keck Foundation, the State of Illinois, and Northwestern University. Infrared spectroscopy and mass spectrometry were conducted at the IMSERC facility at Northwestern University.

## ■ REFERENCES

- (1) Nishikawa, M.; Huang, L. *Hum. Gene Ther.* **2001**, *12*, 861.
- (2) Whitehead, K. A.; Langer, R.; Anderson, D. G. *Nature Rev. Drug Discov.* **2009**, *8*, 129.
- (3) Kim, W. J.; Bonoio, A. C.; Hayakawa, T.; Xia, C.; Kakimoto, M. A.; Pudavar, H. E.; Lee, K. S.; Prasad, P. N. *Int. J. Pharm.* **2009**, *376*, 141.
- (4) Mintzer, M. A.; Simanek, E. E. *Chem. Rev.* **2009**, *109*, 259.
- (5) McAllister, K.; Sazani, P.; Adam, M.; Cho, M. J.; Rubinstein, M.; Samulski, R. J.; DeSimone, J. M. *J. Am. Chem. Soc.* **2002**, *124*, 15198.
- (6) Zhang, K.; Fang, H. F.; Wang, Z. H.; Li, Z.; Taylor, J. S. A.; Wooley, K. L. *Biomaterials* **2010**, *31*, 1805.
- (7) Huang, L.; Li, S. *Nat. Biotechnol.* **1997**, *15*, 620.
- (8) Young, L. S.; Searle, P. F.; Onion, D.; Mautner, V. J. *Pathol.* **2006**, *208*, 299.
- (9) Amiji, M. M. *Polymeric Gene Delivery: Principles and Applications*; CRC Press: Boca Raton, FL, 2004.
- (10) Rosi, N. L.; Giljohann, D. A.; Thaxton, C. S.; Lytton-Jean, A. K. R.; Han, M. S.; Mirkin, C. A. *Science* **2006**, *312*, 1027.
- (11) Giljohann, D. A.; Seferos, D. S.; Prigodich, A. E.; Patel, P. C.; Mirkin, C. A. *J. Am. Chem. Soc.* **2009**, *131*, 2072.
- (12) Ryou, S. M.; Kim, S.; Jang, H. H.; Kim, J. H.; Yeom, J. H.; Eom, M. S.; Bae, J.; Han, M. S.; Lee, K. *Biochem. Biophys. Res. Commun.* **2010**, *398*, 542.
- (13) Mirkin, C. A.; Letsinger, R. L.; Mucic, R. C.; Storhoff, J. J. *Nature* **1996**, *382*, 607.
- (14) Agbasi-Porter, C.; Ryman-Rasmussen, J.; Franzen, S.; Feldheim, D. *Bioconjugate Chem.* **2006**, *17*, 1178.
- (15) Cobley, C. M.; Chen, J. Y.; Cho, E. C.; Wang, L. V.; Xia, Y. N. *Chem. Soc. Rev.* **2011**, *40*, 44.
- (16) Giljohann, D. A.; Seferos, D. S.; Patel, P. C.; Millstone, J. E.; Rosi, N. L.; Mirkin, C. A. *Nano Lett.* **2007**, *7*, 3818.
- (17) Patel, P. C.; Giljohann, D. A.; Daniel, W. L.; Zheng, D.; Prigodich, A. E.; Mirkin, C. A. *Bioconjugate Chem.* **2010**, *21*, 2250.
- (18) Seferos, D. S.; Prigodich, A. E.; Giljohann, D. A.; Patel, P. C.; Mirkin, C. A. *Nano Lett.* **2009**, *9*, 308–311.
- (19) Massich, M. D.; Giljohann, D. A.; Seferos, D. S.; Ludlow, L. E.; Horvath, C. M.; Mirkin, C. A. *Mol. Pharmaceutics* **2009**, *6*, 1934.
- (20) Sokolova, V.; Epple, M. *Angew. Chem. Int. Ed.* **2008**, *47*, 1382.
- (21) Chompoosor, A.; Saha, K.; Ghosh, P. S.; Macarthy, D. J.; Miranda, O. R.; Zhu, Z.-J.; Arcaro, K. F.; Rotello, V. M. *Small* **2010**, *6*, 2246.
- (22) Mohs, A.; Duan, H.; Kairdolf, B.; Smith, A.; Nie, S. *Nano Res.* **2009**, *2*, 500.
- (23) Bhabra, G.; et al. *Nat. Nanotechnol.* **2009**, *4*, 876.
- (24) Nel, A.; Xia, T.; Madler, L.; Li, N. *Science* **2006**, *311*, 622.
- (25) Pan, Y.; Neuss, S.; Leifert, A.; Fischler, M.; Wen, F.; Simon, U.; Schmid, G.; Brandau, W.; Jahnen-Dechent, W. *Small* **2007**, *3*, 1941.
- (26) Zhang, K.; Cutler, J. I.; Zhang, J. A.; Zheng, D.; Auyeung, E.; Mirkin, C. A. *J. Am. Chem. Soc.* **2010**, *132*, 15151.
- (27) Hill, H. D.; Millstone, J. E.; Banholzer, M. J.; Mirkin, C. A. *ACS Nano* **2009**, *3*, 418.
- (28) Hurst, S. J.; Lytton-Jean, A. K. R.; Mirkin, C. A. *Anal. Chem.* **2006**, *78*, 8313.
- (29) Daniel, M. C.; Astruc, D. *Chem. Rev.* **2004**, *104*, 293.
- (30) Link, S.; Wang, Z. L.; El-Sayed, M. A. *J. Phys. Chem. B* **1999**, *103*, 3529.
- (31) Jin, R. C.; Wu, G. S.; Li, Z.; Mirkin, C. A.; Schatz, G. C. *J. Am. Chem. Soc.* **2003**, *125*, 1643.
- (32) Lefevre, P.; Attema, J.; van Bekkum, D. *BMC Mol. Biol.* **2002**, *3*.
- (33) Wyber, J. A.; Andrews, J.; DEmanuele, A. *Pharm. Res.* **1997**, *14*, 750.
- (34) Itaka, K.; Ishii, T.; Hasegawa, Y.; Kataoka, K. *Biomaterials* **2010**, *31*, 3707.
- (35) Davis, M. E.; Zuckerman, J. E.; Choi, C. H. J.; Seligson, D.; Tolcher, A.; Alabi, C. A.; Yen, Y.; Heidel, J. D.; Ribas, A. *Nature* **2010**, *464*, 1067.